No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Teva’s Biosimilar Denosumab Applications Accepted in US and EU
On 8 October 2024, Teva Pharmaceuticals announced that the US FDA and European Medicines Agency (EMA) accepted Biologics Licence and Marketing Authorisation Applications, respectively, for its TVB-009P, biosimilar to Amgen’s Prolia® (denosumab). Both applications...